| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 25002 |
| Drug | Sodium thiosulfate |
| Brand | Pedmarqsi® |
| Indication | Sodium thiosulfate (Pedmarqsi®) is indicated for the prevention of ototoxicity caused by cisplatin chemotherapy in patients one month to < 18 years of age with localised, non-metastatic, solid tumours. |
| Assessment Process | |
| Rapid review commissioned | 08/01/2025 |
| Rapid review completed | 06/02/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of sodium thiosulfate (Pedmarqsi®) compared with the current standard of care. |
| Full HTA commissioned by the HSE | 26/03/2025 |
| Pre-submission consultation with Applicant | 16/04/2025 |
| Full submission received from Applicant | 17/06/2025 |
| Preliminary review sent to Applicant | 23/10/2025 |
| NCPE assessment re-commenced | 21/11/2025 |
| Factual accuracy sent to Applicant | 15/12/2025 |
| NCPE assessment re-commenced | 22/12/2025 |
| NCPE assessment completed | 05/01/2026 |
| NCPE assessment outcome | The NCPE recommends that sodium thiosulfate not be considered for reimbursement unless cost effectiveness can be improved*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Please see the HSE Pricing and Reimbursement Tracker for any updates on the reimbursement status of this drug.